newsfilter
← Latest News
GlobeNewswire·

Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update

On Track to Complete Review of Clinical Development Plans by Mid-2022 Top-Line Results for NX-13 Phase 1b and LABP-104 Phase 1 Trials Remain On Track for Mid-2022 Plans to Announce Timing of Phase 2b Trial of Omilancor Later this Year NEW YORK,